MedTrace Logo

Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes

NCT00509925 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2017-03-10

Study results available
· View outcomes & findings →

Summary

This trial is conducted in Europe. The purpose of this trial is to investigate if there is any change in the mechanism of energy expenditure (i.e. the way in which energy is used) in patients with type 1 diabetes, whilst taking two different, commercially available insulins for the treatment of their diabetes.

Conditions

Interventions

DRUG

insulin detemir

Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection

DRUG

insulin NPH

Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection

DRUG

insulin aspart

Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00509925 on ClinicalTrials.gov